Daiichi Sankyo announces 5-year business plan; names R&D chief

1 April 2016

Japanese pharma major Daiichi Sankyo (TYO: 4568) this week announced its five-year business plan for the fiscal period 2016-2020.

Daiichi Sankyo aspires to be a “Global Pharma Innovator with Competitive Advantage in Oncology” as its 2025 Vision by positioning its innovative pharmaceutical business, centered on oncology, as a core business in order to become a global company developing and

To overcome the patent cliff of the antihypertensive Benicar (olmesartan), one of the firm’s main products, it will make efforts for revenue recovery and profit generation, aiming at revenue of 940 billion yen ($7.83 billion) and operating profit of 100 billion yen in FY 2017. For 2020 it is targeting revenue of 1,200 billion yen and operating profit of 165 billion yen. The five-year plan calls for spending of 500 billion yen on M&A deals and the development of new fields of business like oncology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK